Pelvic inflammatory disease appears early after insertion, affecting about 0.3% to 1.0% of people within 20 days. For many users, the risk profile pairs with persistence, with IUD continuation around 70% at 12 months and a lower discontinuation rate than pill users. Fertility also rebounds quickly after copper IUD removal, typically returning to baseline within 1 to 3 months.
Key Takeaways
- 0.3% to 1.0% risk of pelvic inflammatory disease (PID) within 20 days after insertion (risk window after IUD insertion).
- The CDC’s U.S. medical eligibility criteria classify IUD use as Category 1 (no restriction) for most women living with HIV who are stable on ART and have no active STI.
- The IUD market in 2023 was estimated at $2.8 billion globally (forecast baseline).
- In 2019, 38.9% of U.S. women aged 15–49 using contraception used a LARC method (IUD or implant).
- IUDs have an average duration of up to 5 years for LNG-IUD products (clinical use duration depending on product).
- In a systematic review, continuation rates for IUDs were 70% at 12 months and 60% at 24 months (typical continuation patterns).
- In a Cochrane review, IUDs had higher continuation than short-acting methods at 12 months (effect reported as superior continuation).
- In a large observational study, IUD users had discontinuation rates lower than pill users over 12 months (comparative discontinuation).
- Copper IUD users have an average net fertility return to baseline within 1–3 months after removal (time to return of fertility).
- Levonorgestrel IUD users frequently have lighter menstrual bleeding over time; median time to achieve reduced bleeding is 3–6 months (clinical effect timeline).
- Serious infection requiring hospitalization after insertion is rare, estimated at about 1 per 1,000 insertions (infection complications incidence).
- A 2016 systematic review found LARC (including IUDs) averts more unintended pregnancies per dollar than short-acting methods (cost-effectiveness conclusion with multiple studies).
- In a UK analysis, providing IUDs led to net savings of about £100–£200 per woman compared with some short-acting strategies over the modeled horizon (economic evaluation).
- In 2021, the U.S. contraceptive program market for LARC/IUD was valued at about $1.6 billion in sales (U.S. vendor research estimate).
IUDs offer highly effective contraception with rare serious infection, strong continuation, and fast fertility return after removal.
Related reading
01 · Category
Clinical Outcomes2 stats
01
0.3% to 1.0% risk of pelvic inflammatory disease (PID) within 20 days after insertion (risk window after IUD insertion).
02
The CDC’s U.S. medical eligibility criteria classify IUD use as Category 1 (no restriction) for most women living with HIV who are stable on ART and have no active STI.
Interpretation
Clinical Outcomes Interpretation
Under the Clinical Outcomes category, IUD insertion is linked to a low PID risk of about 0.3% to 1.0% within 20 days, and CDC guidance supports broad eligibility for most women living with HIV who are stable, reinforcing favorable short term and practical clinical outcomes.
More related reading
02 · Category
Market & Adoption3 stats
01
The IUD market in 2023 was estimated at $2.8 billion globally (forecast baseline).
02
In 2019, 38.9% of U.S. women aged 15–49 using contraception used a LARC method (IUD or implant).
03
IUDs have an average duration of up to 5 years for LNG-IUD products (clinical use duration depending on product).
Interpretation
Market & Adoption Interpretation
In the Market and Adoption landscape, the IUD market was about $2.8 billion globally in 2023 and, with 38.9% of US women aged 15–49 using contraception relying on LARC methods in 2019, strong uptake is supported by the practicality of long-use options with LNG-IUDs lasting up to around 5 years.
More related reading
03 · Category
Continuation & Switching5 stats
01
In a systematic review, continuation rates for IUDs were 70% at 12 months and 60% at 24 months (typical continuation patterns).
02
In a Cochrane review, IUDs had higher continuation than short-acting methods at 12 months (effect reported as superior continuation).
03
In a large observational study, IUD users had discontinuation rates lower than pill users over 12 months (comparative discontinuation).
04
Switching from one contraceptive method to another within 12 months occurred for 27% of IUD users in a cohort study (switching as a form of discontinuation).
05
Median time to reinsertion after expulsion or removal was 42 days in a clinical registry study (time-to-next IUD insertion).
Interpretation
Continuation & Switching Interpretation
For the Continuation and Switching category, IUD use shows strong persistence with continuation reaching 70% at 12 months and 60% at 24 months, while only 27% of users switch to another method within 12 months, and when reinsertion is needed it happens quickly with a median of 42 days after expulsion or removal.
More related reading
04 · Category
Safety, Side Effects7 stats
01
Copper IUD users have an average net fertility return to baseline within 1–3 months after removal (time to return of fertility).
02
Levonorgestrel IUD users frequently have lighter menstrual bleeding over time; median time to achieve reduced bleeding is 3–6 months (clinical effect timeline).
03
Serious infection requiring hospitalization after insertion is rare, estimated at about 1 per 1,000 insertions (infection complications incidence).
04
Approximately 10%–20% of IUD users experience unscheduled bleeding in the first months after insertion (spotting/irregular bleeding).
05
Expulsion risk is higher in the postpartum period; postpartum users have about a 2–3x higher expulsion rate compared with non-postpartum users (relative risk reported).
06
In a 2020 review, LNG-IUDs were associated with a ~50% reduction in menstrual blood loss within 3–6 months (bleeding reduction magnitude).
07
Copper IUD users showed mean menstrual blood loss increase of roughly 20%–50% compared with baseline in clinical studies (bleeding impact).
Interpretation
Safety, Side Effects Interpretation
From a safety and side effects perspective, most IUD users experience manageable, time-limited changes such as lighter bleeding with LNG IUDs, where menstrual blood loss drops by about 50% within 3 to 6 months, while serious infection requiring hospitalization is uncommon at roughly 1 per 1,000 insertions.
More related reading
05 · Category
Cost & Value3 stats
01
A 2016 systematic review found LARC (including IUDs) averts more unintended pregnancies per dollar than short-acting methods (cost-effectiveness conclusion with multiple studies).
02
In a UK analysis, providing IUDs led to net savings of about £100–£200 per woman compared with some short-acting strategies over the modeled horizon (economic evaluation).
03
In 2021, the U.S. contraceptive program market for LARC/IUD was valued at about $1.6 billion in sales (U.S. vendor research estimate).
Interpretation
Cost & Value Interpretation
From a cost and value perspective, evidence suggests IUDs can deliver better economic value than short-acting contraception, with a 2016 systematic review showing LARC averts more unintended pregnancies per dollar and a UK analysis estimating net savings of about £100 to £200 per woman, while the broader US LARC or IUD market was valued at roughly $1.6 billion in 2021 sales.
report visual · Comparison
How IUDs compare on key outcomes
IUDs show low early health risks and strong continuation, with most eligibility scenarios classified as no restriction.
Serious infection requiring hospitalization after insertion is rare, estimated at about 1 per 1,000 insertions (infecti1,000
In a systematic review, continuation rates for IUDs were 70% at 12 months and 60% at 24 months (typical continuation pat70%
The CDC’s U.S. medical eligibility criteria classify IUD use as Category 1 (no restriction) for most women living with H1
0.3% to 1.0% risk of pelvic inflammatory disease (PID) within 20 days after insertion (risk window after IUD insertion).0.3%
source-verifiedcdc.gov · pubmed.ncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Iud Statistics. Gitnux. https://gitnux.org/iud-statistics
MLA
Henrik Dahl. "Iud Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/iud-statistics.
Chicago
Henrik Dahl. 2026. "Iud Statistics." Gitnux. https://gitnux.org/iud-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level
+10 additional datasets cited (not shown individually)